Immunic, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IMUX Nasdaq 2834 imux.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunic, Inc.

Immunic (IMUX) Reviews 2025 Performance and Highlights Upcoming Milestones, Shares Up 24.10% - Jan 12th, 2026 2:23 am
Immunic Highlights 2025 Accomplishments and Upcoming Milestones - Jan 7th, 2026 4:30 am
Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Nov 26th, 2025 4:30 am
Immunic: Q3 Earnings Snapshot - Nov 13th, 2025 4:39 am
Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 4:30 am
Datadog, Trade Desk upgraded: Wall Street's top analyst calls - Nov 7th, 2025 7:33 am
Immunic to Participate in Industry and Investor Conferences in November - Oct 29th, 2025 4:30 am
Positive Signs As Multiple Insiders Buy Immunic Stock - Oct 2nd, 2025 8:18 am
Immunic to Participate in Scientific and Investor Conferences in October - Oct 1st, 2025 4:30 am
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - Sep 25th, 2025 4:30 am
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - Sep 9th, 2025 4:30 am
Immunic to Participate in Investor and Scientific Conferences in September - Sep 4th, 2025 4:30 am
Can Immunic (NASDAQ:IMUX) Afford To Invest In Growth? - Sep 1st, 2025 6:36 am
Immunic: Q2 Earnings Snapshot - Aug 7th, 2025 4:37 am
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 7th, 2025 4:30 am
Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial - Jul 25th, 2025 10:22 am
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - Jun 24th, 2025 4:30 am
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - Jun 5th, 2025 4:30 am
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering - Jun 3rd, 2025 2:01 pm
Immunic to Participate in Investor, Scientific and Industry Conferences in June - Jun 2nd, 2025 4:30 am